The Claim
Among obese adults treated with tirzepatide or semaglutide, White individuals have a higher proportion of achieving ≥15% weight loss compared to Black or Hispanic individuals, with 91.2% of high responders being White, 6.0% Black, and 1.6% Hispanic.
What the research says
Challenges is higher
Challenge is ahead, but a single strong supporting study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese adults using tirzepatide or semaglutide for weight loss, 91.2% of those who lost at least 15% of their body weight are White, while 6.0% are Black and 1.6% are Hispanic.
See the scientific wording
Among obese adults, White individuals are more likely than Black or Hispanic individuals to achieve high weight loss (≥15%) with either tirzepatide or semaglutide, with 91.2% of high responders being White compared to 6.0% Black and 1.6% Hispanic for tirzepatide, suggesting racial disparities in treatment response.
The body breaks down these weight-loss drugs at different rates depending on genetic traits, and the receptors they target respond differently in some people, leading to less appetite suppression and fat loss in certain groups.
What the research says
1 studyStudy: Weight-loss dynamics with tirzepatide versus semaglutide
The study says White patients tended to lose more weight than Black or Hispanic patients on these drugs, but it doesn’t give the exact numbers the claim uses—so those numbers can’t be trusted even if the general trend might be real.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.